



شبكة المعلومات الجامعية

Ain Shams University

Information Network

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

جامعة عين شمس

شبكة المعلومات الجامعية

@ ASUNET



شبكة المعلومات الجامعية

جامعة عين شمس

التوثيق الالكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
على هذه الأفلام قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأفلام بعيدا عن الغبار

في درجة حرارة من ١٥-٢٥ مئوية ورطوبة نسبية من ٢٠-٤٠%

To be Kept away from Dust in Dry Cool place of
15-25- c and relative humidity 20-40%



شبكة المعلومات الجامعية التوثيق الالكتروني والميكرو فيلم

بعض الوثائق الأصلية تالفة

بالرسالة صفحات لم ترد بالاصل

616, 9944

Recent Advances In Prognostic Markers Of Haematologic Malignancies

Essay

By

Mariam Maged Fathy El Haddad

M.B.B.Ch.

Submitted for partial fulfillment of M.Sc. degree

in

Clinical Pathology

Supervisors

Dr. Hanaa Hamed Arnaout, M.D.

Professor of Clinical Pathology

Faculty of Medicine

Cairo University

Dr. Basma Mostafa Elgamal, M.D.

Assistant Professor of Clinical Pathology

National Cancer Institute

Cairo University

2010

Yno-
CP

اجتماع لجنة الحكم على الرسالة المقدمة من
الطبيب / عزيم ماجد فتحى محمد ابراهيم
توظيفة للحصول على درجة الماجستير / الدكتوراه
في الباثولوجيا الكلينيكية والكيمياء

Recent advances in prognostic markers of hematologic malignancies
بالتة الانجليزية

بالتة العربية : الخطوات الربية من الربية الشؤبة
لمسجلات الربية

بناء على موافقة الجامعة بتاريخ ٢٠١٠ / ١٢ / ٢٩ تم تشكيل لجنة الفحص والمناقشة
للرسالة المذكورة أعلاه على النحو التالي :-
١. د. صالح جند انصار - الباثولوجيا الكلينيكية والكيمياء - مدير المركز من المشرفين
٢. د. تيسير كادى - الباثولوجيا الكلينيكية والكيمياء - مدير المركز من مفتحي داخلي
٣. د. سكرومى موزى - الباثولوجيا الكلينيكية والكيمياء - مدير المركز من مفتحي خارجي

بعد فحص الرسالة بواسطة كل عضو منفردا وتغاية تقارير منفردة لكل منهم انعقدت اللجنة
مجتمعة فى يوم الاربعاء بتاريخ ٢٠١١ / ١ / ٢٤ بقسم الباثولوجيا الكلينيكية
بكلية الطب - جامعة القاهرة وذلك لمناقشة المناوبين ، جلسة طانية فى موضوع الرسالة والذاتج
التي توصل اليها وكذلك الأسس العلمية التي قام عليها البحث .

قرار اللجنة : قبول الرسالة

المفتحن الخارجيين

المفتحن الداخليين

توقيع أعضاء اللجنة :-
المشرف للمبحث

د. مستعد

د. سعيد

عصام

ABSTRACT

Hematological malignancies comprise a group of neoplasms that arise through malignant transformation of bone marrow derived cells. Diagnosis of hematologic malignancies presents a challenge due to the complexity of hematopoiesis that gives rise to a number of biologically and clinically distinct neoplasms.

In the last decades, molecular markers supplied by immunophenotyping and cytogenetic/molecular genetic analysis have become of crucial importance for understanding pathogenesis, making a precise diagnosis, determining prognosis, choosing treatment and developing new forms of treatment.

Advances in molecular genetic research enabled a better understanding of the mechanisms by which chromosomal events cause blood malignancies. New molecular discoveries are also helpful to direct research toward novel targeted therapies.

Key words: Haematological malignancies, molecular markers, myeloid neoplasms, lymphoid neoplasms, WHO classification, immunophenotyping, cytogenetics, molecular techniques.

ACKNOWLEDGEMENTS

*First of all great thanks to Allah for guiding
my efforts in this work.*

I would like to express my deep thanks and sincere gratitude to Prof. Dr. Hanaa Hamed Arnaout, Prof. of Clinical and Chemical Pathology, Cairo University. She kindly offered me her valuable meticulous scientific help, precious time, effort and constant support which were the corner stone in the completion of this work. I am greatly honored and pleased to have had the opportunity to work with her.

My deepest appreciation and thanks are offered to Dr. Basma Mostafa Elgamal, assistant professor of Clinical and Chemical Pathology, National Cancer Institute, Cairo University for her kind supervision, valuable suggestions, advices, continuous support and generous help which she offered me whenever I needed her during work in this study.

LIST OF CONTENTS

	Pages
INTRODUCTION	1
AIM OF WORK	3
CHAPTER (1)	4
HEMATOLOGICAL MALIGNANCIES	
Definition	4
Classification :	
I. Myeloid Neoplasms	7
II. Lymphoid Neoplasms	23
CHAPTER (2)	35
DIAGNOSTIC AND PROGNOSTIC MOLECULAR MARKERS IN HAEMATOLOGICAL MALIGNANCIES	
I. Morphological examination of peripheral blood and bone marrow and cytochemistry	35
II. Immunophenotyping	38
III. Cytogenetic Analysis	50
CHAPTER (3)	79
Myeloid Neoplasms	
I. Myeloproliferative neoplasms (MPN):	
1. Chronic myelogenous leukemia (CML)	73
2. Chronic neutrophilic leukemia (CNL)	80
3. Polycythemia vera (PV)	83
4. Primary myelofibrosis (PMF)	87
5. Essential thrombocythaemia (ET)	93
6. Chronic eosinophilic leukemia (CEL,NOS)	99
7. Mastocytosis	105
8. Myeolrpoliferative neoplasm, (MPN,U)	110

II. Myeloid and Lymphoid Neoplasms with Eosinophilia and Abnormalities of PDGFRA, PDGFRB or FGFR1	
1. Myeloid and lymphoid neoplasm with PDGFRA rearrangement	113
2. Myeloid and lymphoid neoplasm with PDGFRB rearrangement	117
3. Myeloid and lymphoid neoplasm with FGFR1 abnormalities	120
III. Myeloproliferative/ Myelodysplastic (MPN/MDS) Neoplasms	
1. Chronic myelomonocytic leukaemia (CMML)	123
2. Atypical Chronic myeloid leukaemia, (aCML)	128
3. Juvenile myelomonocytic leukaemia (JMML)	131
4. Myelodysplastic/Myeloproliferative neoplasm, unclassifiable (MDS/MPN,U)	135
Refractory anaemia with ring sideroblasts (RARS) associated with marker thrombocytosis (RARS-T)	137
IV. Myelodysplastic Syndromes	
1. Refractory cytopenia with unilineage dysplasia (RCUD)	139
2. Refractory anaemia with ring sideroblasts (RARS)	143
3. Refractory cytopenia with multilineage dysplasia(RCMD)	146
4. Refractory anaemia with excess blasts (RAEB)	148
5. Myelodysplastic syndrome with isolated del (5q)	151
6. Myelodysplastic syndrome, unclassifiable (MDS-U)	154
7. Childhood myelodysplastic syndrome	156
V. Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	
1. Acute myeloid leukaemia with recurrent genetic abnormalities	160
2. Acute myeloid leukaemia with myelodysplasia-related changes	180
3. Therapy-related myeloid neoplasm (t-AML)	183
4. Acute myeloid leukaemia, not otherwise specified (AML, NOS)	186
5. Myeloid sarcoma	187
6. Myeloid proliferations related to Down syndrome	190

7. Blastic plasmacytoid dendritic cell neoplasm (BPDC)	195
VI. Acute Leukaemias of Ambiguous Lineage	198

CHAPTER (4)

LYMPHOID NEOPLASMS

Precursor Lymphoid Neoplasms

I. B-lymphoblastic leukaemia/lymphoma, not otherwise specified	201
II. B-lymphoblastic leukaemia/lymphoma, with recurrent genetic abnormalities	206
III. T-lymphoblastic leukaemia/lymphoma	220

Mature B-Cell neoplasms

I. Chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL)	225
II. B-Cell prolymphocytic leukaemia (B-PLL)	234
III. Hairy cell leukaemia (HCL)	237
IV. Heavy chain diseases (HCD)	241
V. Plasma cell neoplasms	242
1. Monoclonal gammopathy of undetermined significance (MGUS)	243
2. Plasma cell myeloma	246
3. Solitary plasmacytoma of bone	257
4. Extrasosseous (extramedullary) plasmacytoma	258
5. Monoclonal immunoglobulin deposition diseases (MIDD)	259
6. Osteosclerotic myeloma (POEMS syndrome)	260
VI. Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue	262
VII. Follicular lymphoma (FL)	266
VIII. Mantle cell lymphoma (MCL)	271
IX. Diffuse large B-cell lymphoma, not otherwise specified (DLBCL)	276
X. Burkitt Lymphoma (BL)	281

Mature T and NK-Cell Neoplasms	
I. T-cell prolymphocytic leukaemia (T-PLL)	287
II. T-cell large granular lymphocytic leukaemia (T-LGL)	290
III. Chronic lymphoproliferative disorders of NK cells (CLPD-NK)	393
IV. Adult T-cell leukaemia/lymphoma (ATLL)	296
V. Mycosis fungoides (MF)	299
VI. Sezary syndrome (SS)	303
Hodgkin Lymphoma	305
I. Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)	307
II. Classical Hodgkin lymphoma (CHL)	310
1. Nodular sclerosis classical Hodgkin lymphoma (NSCHL)	315
2. Mixed cellularity classical Hodgkin lymphoma (MCCHL)	317
3. Lymphocyte-rich classical Hodgkin lymphoma (LRCHL)	319
4. Lymphocyte-depleted classical Hodgkin lymphoma (LDCHL)	321
Histiocytic and Dendritic Cell Neoplasms	
Tumours Derived from Langerhan's Cells	
I. Langerhan's cell histiocytosis	323
II. Langerhan's cell sarcoma	327
SUMMARY	328
REFERENCES	331
ARABIC SUMMARY	1-2

LIST OF TABLES

Table No.	Title	Page
1.1	Classification of myeloid malignancies.	7
1.2	Classification of chronic myeloproliferative diseases.	9
1.3	WHO (2001): Myelodysplastic/Meloproliferative diseases.	12
1.4	Classification of Myelodysplastic syndromes.	14
1.5	Classification of AML.	17
2.1	Cytochemical stains of use in the diagnosis and classification of acute leukaemia.	36
2.2	Flow Cytometry Markers for Acute Leukemia Diagnosis.	41
2.3	WHO 2008 criteria for a diagnosis of mixed phenotype acute leukaemia.	42
2.4	Subtype classification of B-ALL based on sequential antigen expression during B-cell ontogenesis and its prognostic significance.	42
2.5	Subtype classification of T-ALL based on sequential antigen expression during T-cell ontogenesis and its prognostic significance.	43
2.6	Immunophenotypic Markers Used in Diagnosis of Malignant Lymphomas	44
2.7	Summary of molecular genetic techniques used in investigation of haematologic malignancies.	52
2.8	Common cytogenetic and molecular genetic changes in leukemias and lymphomas.	55
2.9	Incidence of Chromosome Changes in Primary and t-MDS.	58
2.10	Prognosis in Myelodysplastic Syndrome According to Cytogenetic Findings.	59
2.11	The different gene mutations with their frequent cytogenetic findings.	61
2.12	Genetic Abnormalities in Normal Cytogenetic AML.	64
2.13	Dysregulation of proteins involved in cell cycle regulation and apoptosis.	66

Table No.	Title	Page
2.14	Common chromosomal aberrations in CLL, known affected genes and their impact on prognosis.	69
2.15	Cytogenetic prognostic groups in plasma cell myeloma.	72
4.1	The immunophenotype of CLL: tests used as basis for a scoring system.	227
4.2	CLL score in B-cell disorders.	228
4.3	Rai Classification System for CLL.	232
4.4	Binet Classification for CLL.	232
4.5	Translocation and Cyclin D groups in plasma cell myelomas.	251
4.6	Myeloma staging system.	255
4.7	International staging system for plasma cell myeloma.	256
4.8	Follicular lymphoma grading.	269
4.9	International Prognostic Index for aggressive lymphomas.	279
4.10	Clinical staging system for mycosis fungoides and Sezary syndrome, as recently proposed by the ISCL- EORTC.	300
4.11	Coastward revision of the Ann Arbor staging system.	306